202 related articles for article (PubMed ID: 37968169)
1. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
3. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
6. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
7. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
[TBL] [Abstract][Full Text] [Related]
8. Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
Miyake M; Nishimura N; Fujii T; Fujimoto K
Int J Urol; 2023 Nov; 30(11):944-957. PubMed ID: 37522629
[TBL] [Abstract][Full Text] [Related]
9. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
[TBL] [Abstract][Full Text] [Related]
10. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
[TBL] [Abstract][Full Text] [Related]
11. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
12. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
13. OncoTherad
Reis IB; Tibo LHS; de Souza BR; Durán N; Fávaro WJ
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5025-5036. PubMed ID: 36322290
[TBL] [Abstract][Full Text] [Related]
14. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
15. [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer].
Leucht K; Foller S; Grimm MO
Urologe A; 2021 Nov; 60(11):1400-1408. PubMed ID: 34709440
[TBL] [Abstract][Full Text] [Related]
16. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
19. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
